BIO
The burgeoning field of mRNA therapeutics demands specialised expertise and facilities.
In a recent webinar, Melanie Cerullo, Chief Quality and Regulatory Officer at ReciBioPharm, offered an inside look at our state-of-the-art Watertown, Massachusetts facility, exploring how its design meets the unique challenges of mRNA production head-on.
Key advantages for mRNA development at Watertown:
- End-to-end capabilities: From nucleic acid production to lipid nanoparticle formulation and sterile fill/finish, Watertown offers comprehensive services under one roof, streamlining development timelines.
- Quality-centric culture: Built to meet stringent regulatory standards, the facility ensures seamless transitions from early-phase to commercial production, with a flexible approach tailored to each project's phase.
- Collaborative partnership: ReciBioPharm's customer-centric approach includes dedicated project management, transparent communication and regulatory CMC support, empowering clients throughout the entire development journey.
A glimpse into the future of mRNA manufacturing
At ReciBioPharm’s Watertown facility, we're committed to advancing mRNA manufacturing to make life-saving therapies more accessible to patients. To revolutionise how these critical therapies are produced, we are leading the development of next-generation continuous manufacturing technologies, supported by an FDA grant.
Discover the next generation of mRNA production at our Watertown facility in our on-demand webinar.
Fill in the form below and access the video: